新型冠状病毒肺炎中的炎症：从发病机制到治疗
Inflammation in COVID-19: from pathogenesis to treatment.
作者信息
Wong Rebecca S Y
机构信息
Faculty of Medicine, SEGi University No. 9 Jalan Teknologi, Taman Sains Selangor, Kota Damansara, PJU 5, 47810 Petaling Jaya, Selangor, Malaysia.
出版信息
Int J Clin Exp Pathol. 2021 Jul 15;14(7):831-844. eCollection 2021.
Abstract
The coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020 by the World Health Organization (WHO). To date, there were > 163 million confirmed cases of COVID-19 and the disease has claimed > 3.3 million lives globally. As with many other diseases, inflammation is a key feature of COVID-19. When inflammation is overwhelming, it may lead to unfavorable outcomes or even death. Scientists all over the world are working tirelessly in search of therapeutic strategies to suppress or modulate inflammation in COVID-19. This review gives an overview of the role of inflammation in COVID-19. It also critically examines the various treatment approaches that target the immune system and inflammation in COVID-19, as well as highlights the key findings in the numerous studies conducted thus far.
摘要
2020年3月，世界卫生组织（WHO）宣布2019冠状病毒病（COVID-19）为大流行病。截至目前，全球COVID-19确诊病例已超过1.63亿例，该疾病已导致全球超过330万人死亡。与许多其他疾病一样，炎症是COVID-19的一个关键特征。当炎症反应过度时，可能会导致不良后果甚至死亡。世界各地的科学家们正在不懈努力，寻找抑制或调节COVID-19炎症的治疗策略。本综述概述了炎症在COVID-19中的作用。它还批判性地审视了针对COVID-19免疫系统和炎症的各种治疗方法，并突出了迄今为止众多研究所取得的关键发现。
相似文献
1
Inflammation in COVID-19: from pathogenesis to treatment.
Int J Clin Exp Pathol. 2021 Jul 15;14(7):831-844. eCollection 2021.
2
Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
J Med Internet Res. 2020 Aug 13;22(8):e20193. doi: 10.2196/20193.
3
The Impact of Deranged Glucose Metabolism and Diabetes in the Pathogenesis and Prognosis of the Novel SARS-CoV-2: A Systematic Review of Literature.
Curr Diabetes Rev. 2022;18(3):e060821195355. doi: 10.2174/1573399817666210806104349.
4
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
5
Immunologic aspects of characteristics, diagnosis, and treatment of coronavirus disease 2019 (COVID-19).
J Biomed Sci. 2020 Jun 4;27(1):72. doi: 10.1186/s12929-020-00663-w.
6
Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Life Sci. 2020 Sep 15;257:118102. doi: 10.1016/j.lfs.2020.118102. Epub 2020 Jul 18.
7
Molecular Insights into COVID-19 Pathophysiology, Immune Pathogenesis, Detection, and Treatment.
DNA Cell Biol. 2021 Jul;40(7):858-868. doi: 10.1089/dna.2021.0068. Epub 2021 May 14.
8
Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2.
Indian J Clin Biochem. 2021 Jan;36(1):3-22. doi: 10.1007/s12291-020-00953-y. Epub 2021 Jan 3.
9
Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
Biochem Pharmacol. 2020 Oct;180:114169. doi: 10.1016/j.bcp.2020.114169. Epub 2020 Jul 23.
10
Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
Int J Mol Sci. 2020 Nov 20;21(22):8803. doi: 10.3390/ijms21228803.
引用本文的文献
1
Impact of the COVID-19 pandemic on admission trends, diagnosis patterns, and demographics of ischemic heart disease patients: a retrospective study.
J Cardiothorac Surg. 2025 Aug 28;20(1):346. doi: 10.1186/s13019-025-03564-x.
2
Lower cancer incidence three years after COVID-19 infection in a large veteran population.
PLoS One. 2025 Aug 25;20(8):e0318131. doi: 10.1371/journal.pone.0318131. eCollection 2025.
3
Medical implications of gas producing probiotics: anti-inflammation and immunity enhancement for ameliorating disease severity.
Med Gas Res. 2024 Sep 1;14(3):140-141. doi: 10.4103/mgr.MEDGASRES-D-23-00041. Epub 2024 Mar 20.
4
Design and synthesis of novel pyrimidine-pyrazole hybrids with dual anticancer and anti-inflammatory effects targeting BRAFV600E and JNK.
Mol Divers. 2025 Feb 22. doi: 10.1007/s11030-025-11121-w.
5
TRIM7 ubiquitinates SARS-CoV-2 membrane protein to limit apoptosis and viral replication.
Nat Commun. 2024 Nov 30;15(1):10438. doi: 10.1038/s41467-024-54762-5.
6
An Overview of Pediatric Pulmonary Complications During COVID-19 Pandemic: A Lesson for Future.
Immun Inflamm Dis. 2024 Nov;12(11):e70049. doi: 10.1002/iid3.70049.
7
Frequency and Association of Polymorphisms in F2, F7, and PROS1 Coagulation Genes with Disease Severity in Coronavirus Disease 2019.
Clin Appl Thromb Hemost. 2024 Jan-Dec;30:10760296241295731. doi: 10.1177/10760296241295731.
8
TP53 Codon 72 Polymorphism Impacts Macrophage Activation through Reactive Oxygen Species-Dependent Cell Signaling Alterations.
J Immunol. 2024 Dec 15;213(12):1844-1857. doi: 10.4049/jimmunol.2400212.
9
Synthesis, Characterization, and Biological Activity of New 4'-Functionalized Bis-Terpyridine Ruthenium(II) Complexes: Anti-Inflammatory Activity Advances.
ChemMedChem. 2025 Feb 1;20(3):e202400680. doi: 10.1002/cmdc.202400680. Epub 2024 Nov 21.
10
COVID-19 outcomes among patients with dementia and age-matched controls who were hospitalized in 21 US health-care systems.
Alzheimers Dement. 2024 Sep;20(9):6395-6406. doi: 10.1002/alz.14136. Epub 2024 Jul 29.
本文引用的文献
1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0.
2
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.
3
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue.
Emerg Microbes Infect. 2021 Dec;10(1):266-276. doi: 10.1080/22221751.2021.1884503.
4
Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients.
Cell Rep. 2021 Feb 9;34(6):108728. doi: 10.1016/j.celrep.2021.108728. Epub 2021 Jan 21.
5
Adaptive immunity to SARS-CoV-2 and COVID-19.
Cell. 2021 Feb 18;184(4):861-880. doi: 10.1016/j.cell.2021.01.007. Epub 2021 Jan 12.
6
Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.
Ann Rheum Dis. 2021 Jul;80(7):943-951. doi: 10.1136/annrheumdis-2020-219517. Epub 2021 Jan 21.
7
Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.
N Engl J Med. 2021 Jan 21;384(3):289-291. doi: 10.1056/NEJMe2034495.
8
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
9
Hyperinflammation and Immune Response Generation in COVID-19.
Neuroimmunomodulation. 2020;27(2):80-86. doi: 10.1159/000513198. Epub 2020 Dec 18.
10
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
Zotero 插件